Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on February 12, 2026, declared Interim Dividend of 1.50 per equity share.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma's Board approved Q3FY26 results with consolidated revenue from operations rising ~36% YoY to ₹6,473 million (from ₹4,748 million), driven by a sharp jump in formulations export (₹421.4 Cr vs ₹285.8 Cr in Q3FY25). Consolidated net profit for the quarter grew ~14% to ₹151.3 Crore, with EBITDA (incl. other income) at ₹216.8 Crore and 30.7% margin. However, 9MFY26 PAT fell ~22% YoY to ₹1,149.5 Crore from ₹1,477.4 Crore, weighed down by a weak Q2. The Board declared a third interim dividend of ₹1.50/share (75% on face value of ₹2), with record date Feb 18, 2026 and payment from Feb 26, 2026. Other key items include completion of the 35.75% Adcock Ingram (South Africa) acquisition for US$225 million in Nov 2025, superannuation of CFO S.V.V.N. Appa Rao and appointment of Amit Parekh as new CFO, re-appointment of four directors, and incorporation of a new Chile subsidiary with up to US$300,000 investment.
Strong Q3 revenue growth and a consistent third interim dividend are shareholder-friendly, but the sharp 9M profit decline and large South Africa acquisition introduce execution risk. Near-term, the stock may react to the mixed earnings — robust top-line offset by softer cumulative bottom-line and CFO transition.